Spis treści:
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 43 | / | 2025 | ||||||||
| Date of issue: | 2025-10-07 | ||||||||||
| Short name of the issuer | |||||||||||
| KRKA | |||||||||||
| Subject | |||||||||||
| Conclusion regarding perindopril litigation | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 17 ust. 1 MAR | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| According to Article 17 of Regulation (EU) No 596/2014 Krka, d. d., Novo mesto hereby informs the interested public that based on the analysis of previous decisions in the matter and in order to avoid further litigation costs for the parties, Krka has settled the dispute regarding its product perindopril before the Court of Justice of the EU. The case before the Court of Justice of the EU is thus finally closed. Krka published the announcements considering this case on 26 November 2008, 6 January 2009, 8 July 2009, 3 July 2014, 12 December 2018 and 1 July 2024. |
|||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| KRKA, TOVARNA ZDRAVIL D.D. | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| KRKA | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) |
||||||||||||
| 8501 | Nove Mesto | ||||||||||||
| (post code) | (city) | ||||||||||||
| Smarjeska | 6 | ||||||||||||
| (street) | (number) | ||||||||||||
| +386 7 331 21 11 | +386 7 332 15 37 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nie dotyczy | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2025-10-07 | Jože Colarič | President of the Managemen Board and CEO | |||
Źródło:Komunikaty spółek (ESPI)
